Company intelligence / Profile preview
Zhejiang CDMO Pharmaceutical
Jinhua, Zhejiang, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Zhejiang CDMO Pharmaceutical is conducting early-stage clinical trials, such as a Phase 1 study on "HQ2216 injection" for nervous system diseases, focusing on safety, tolerability, and PK/PD profile in healthy subjects.
- Therapeutic areas
- NeurologyEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zhejiang CDMO Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang CDMO Pharmaceutical.